Turn Therapeutics Inc.(TTRX)Earnings, Financials & Key Ratios
TTRX•NASDAQ
Price updated Jun 19, 2026
AboutGlobal Health Solutions, Inc., doing business as Turn Therapeutics, operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. Global Health Solutions, Inc. was incorporated in 2015 and is based in Westlake Village, California.Show more
- Revenue$0
- EBITDA-$6M-231.8%
- Net Income-$3M-80.6%
- EPS (Diluted)-0.23-76.9%
- ROE-141.67%
TTRX Key Insights
Turn Therapeutics Inc. (TTRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 91 (top 9%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 17.2x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TTRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TTRX Price & Volume
Turn Therapeutics Inc. (TTRX) stock price & volume — 10-year historical chart
Loading chart...
TTRX Growth Metrics
Turn Therapeutics Inc. (TTRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-144.39%
5 Years-144.39%
3 Years-144.39%
Last Year-156.24%
TTRX Recent Earnings
Turn Therapeutics Inc. (TTRX) EPS & revenue vs analyst estimates — last 3 quarters
●Beat EPS 0/3 qtrs (0%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.03-50.0%
$0.02
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$0.09-76.5%
$0.05
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.07
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.03vs $0.02-50.0% | — |
| Q2 2026 | Mar 31, 2026 | $0.09vs $0.05-76.5% | — |
| Q4 2025 | Nov 13, 2025 | $0.07 | — |
Based on last 3 quarters of dataView full earnings history →
TTRX Peer Comparison
Turn Therapeutics Inc. (TTRX) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 ARQT | 3.28B | 26.21 | -201.62 | 91.34% | -0.57% | -1.41% | 0.03 | |
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 RVMD | 34.65B | 162.99 | -27.39 | -83.22% | 0.10 | |||
 VRTX | 114.88B | 451.63 | 29.48 | 9.57% | 35.4% | 23.93% | 0.21 | |
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 |
Compare TTRX vs Peers
Turn Therapeutics Inc. (TTRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TTRX Income Statement
Turn Therapeutics Inc. (TTRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 42.28K |
COGS % of Revenue | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | -42.28K▲ 0% |
Gross Margin % | - | - | - | - |
Gross Profit Growth % | - | - | - | - |
Operating Expenses | 2.31M | 1.8M | 5.86M | 6.68M |
OpEx % of Revenue | - | - | - | - |
Selling, General & Admin | 2.3M | 1.55M | 5.59M | 6.31M |
SG&A % of Revenue | - | - | - | - |
Research & Development | 7.5K | 245.96K | 265.57K | 365.75K |
R&D % of Revenue | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 |
Operating Income | -2.31M▲ 0% | -1.8M▲ 22.1% | -5.86M▼ 226.0% | -6.72M▲ 0% |
Operating Margin % | - | - | - | - |
Operating Income Growth % | - | 22.14% | -226% | - |
EBITDA | -2.26M | -1.75M | -5.81M | -6.68M |
EBITDA Margin % | - | - | - | - |
EBITDA Growth % | - | 22.73% | -231.83% | - |
D&A (Non-Cash Add-back) | 43.92K | 47.48K | 52.75K | 42.28K |
EBIT | -2.31M | -1.8M | -5.86M | -6.72M |
Net Interest Income | 15.88K | 28.71K | 29.58K | 74.1K |
Interest Income | 15.88K | 28.71K | 29.58K | 74.1K |
Interest Expense | 0 | 0 | 0 | 0 |
Other Income/Expense | 15.88K | 28.71K | 2.66M | 2.88M |
Pretax Income | -2.29M▲ 0% | -1.77M▲ 22.9% | -3.19M▼ 80.6% | -3.84M▲ 0% |
Pretax Margin % | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% |
Net Income | -2.29M▲ 0% | -1.77M▲ 22.9% | -3.19M▼ 80.6% | -3.84M▲ 0% |
Net Margin % | - | - | - | - |
Net Income Growth % | - | 22.85% | -80.62% | - |
Net Income (Continuing) | -2.29M | -1.77M | -3.19M | -3.84M |
Discontinued Operations | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.17▲ 0% | -0.13▲ 23.5% | -0.23▼ 76.9% | -0.13▲ 0% |
EPS Growth % | - | 23.53% | -76.92% | - |
EPS (Basic) | -0.17 | -0.13 | -0.23 | - |
Diluted Shares Outstanding | 13.25M | 13.42M | 13.74M | 29.48M |
Basic Shares Outstanding | 13.25M | 13.42M | 13.74M | 29.48M |
Dividend Payout Ratio | - | - | - | - |
TTRX Balance Sheet
Turn Therapeutics Inc. (TTRX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|
Total Current Assets | 1.2M | 1.1M | 5.2M | 11.45M |
Cash & Short-Term Investments | 1.18M | 872.6K | 5.08M | 11.22M |
Cash Only | 1.18M | 872.6K | 5.08M | 11.22M |
Short-Term Investments | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - |
Other Current Assets | 20.82K | 225.32K | 0 | 235.17K |
Total Non-Current Assets | 811.74K | 950.97K | 6.97M | 7.19M |
Property, Plant & Equipment | 33.22K | 120.45K | 0 | 67.57K |
Fixed Asset Turnover | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 |
Intangible Assets | 769.94K | 821.93K | 922.17K | 919.95K |
Long-Term Investments | 0 | 0 | 0 | 52.7K |
Other Non-Current Assets | 8.58K | 8.58K | 6.04M | 6.2M |
Total Assets | 2.01M▲ 0% | 2.05M▲ 1.8% | 12.16M▲ 493.6% | 18.64M▲ 0% |
Asset Turnover | - | - | - | 0.00x |
Asset Growth % | - | 1.75% | 493.6% | 0% |
Total Current Liabilities | 489.78K | 707.93K | 6M | 5.13M |
Accounts Payable | 0 | 0 | 2.93M | 2.32M |
Days Payables Outstanding | - | - | - | 16.2K |
Short-Term Debt | 0 | 0 | 0 | 47.8K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
Other Current Liabilities | 464.62K | 667.27K | 3.03M | 2.77M |
Current Ratio | 2.45x | 1.55x | 0.87x | 2.23x |
Quick Ratio | 2.45x | 1.55x | 0.87x | 2.23x |
Cash Conversion Cycle | - | - | - | - |
Total Non-Current Liabilities | 1.44M | 1.52M | 1.47M | 7.4M |
Long-Term Debt | 0 | 0 | 0 | 5.94M |
Capital Lease Obligations | 0 | 80.38K | 34.08K | 160K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 |
Total Liabilities | 1.93M | 2.23M | 7.48M | 12.53M |
Total Debt | 25.16K | 121.04K | 80.38K | 6.01M |
Net Debt | -1.16M | -751.56K | -5M | -5.21M |
Debt / Equity | 0.29x | - | 0.02x | 0.98x |
Debt / EBITDA | - | - | - | -0.90x |
Net Debt / EBITDA | - | - | - | 0.78x |
Interest Coverage | - | - | - | - |
Total Equity | 85.77K▲ 0% | -177.43K▼ 306.9% | 4.69M▲ 2741.4% | 6.12M▲ 0% |
Equity Growth % | - | -306.87% | 2741.42% | 0% |
Book Value per Share | 0.01 | -0.01 | 0.34 | 0.21 |
Total Shareholders' Equity | 85.77K | -177.43K | 4.69M | 6.12M |
Common Stock | 1.32K | 1.34K | 2.94K | 2.98K |
Retained Earnings | -17.43M | -19.2M | -22.39M | -23.36M |
Treasury Stock | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 |
TTRX Cash Flow Statement
Turn Therapeutics Inc. (TTRX) cash flow — operating, investing & free cash flow history
| Metric | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|
Cash from Operations | -1.38M | -1.36M | -2.56M | -3.9M |
Operating CF Margin % | - | - | - | - |
Operating CF Growth % | - | 1.19% | -88.27% | 0% |
Net Income | -2.29M | -1.77M | -3.19M | -3.84M |
Depreciation & Amortization | 43.92K | 47.48K | 52.75K | 42.28K |
Stock-Based Compensation | 640.26K | 352.83K | 419.25K | 0 |
Deferred Taxes | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 662 | 8.65K | -2.21M | -2.04M |
Working Capital Changes | 229.74K | -1.86K | 2.37M | 1.94M |
Change in Receivables | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 2.26M | 1.67M |
Cash from Investing | -44.31K | -99.47K | -152.99K | -165.21K |
Capital Expenditures | -44.31K | -99.47K | 0 | -165.21K |
CapEx % of Revenue | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 |
Investments | - | - | - | - |
Other Investing | 0 | 0 | -152.99K | 0 |
Cash from Financing | 500K | 1.15M | 6.92M | 13.71M |
Debt Issued (Net) | 0 | 0 | 0 | 6.72M |
Equity Issued (Net) | 500K | 1.15M | 6.92M | 5.92M |
Dividends Paid | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 1.07M |
Net Change in Cash | -921.99K▲ 0% | -308.4K▲ 66.6% | 4.2M▲ 1463.0% | 11.22M▲ 0% |
Free Cash Flow | -1.42M▲ 0% | -1.46M▼ 2.7% | -2.72M▼ 85.9% | -3.9M▲ 0% |
FCF Margin % | - | - | - | - |
FCF Growth % | - | -2.73% | -85.92% | - |
FCF per Share | -0.11 | -0.11 | -0.20 | -0.13 |
FCF Conversion (FCF/Net Income) | 0.60x | 0.77x | 0.80x | 1.02x |
Interest Paid | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 |
TTRX Key Ratios
Turn Therapeutics Inc. (TTRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2024 | 2025 | TTM |
|---|---|---|---|
Return on Equity (ROE) | - | -141.67% | -116.83% |
Return on Invested Capital (ROIC) | - | - | 634.82% |
Debt / Equity | - | 0.02x | 0.98x |
FCF Conversion | 0.77x | 0.80x | 1.02x |
Related:TTRX Dividend History·TTRX Revenue History·TTRX Price History·TTRX P/E History·TTRX Financial Ratios·TTRX Institutional Holders
TTRX Frequently Asked Questions
Turn Therapeutics Inc. (TTRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Turn Therapeutics Inc. (TTRX) grew revenue by 0.0% over the past year. Growth has been modest.
Turn Therapeutics Inc. (TTRX) reported a net loss of $3.8M for fiscal year 2025.
Dividend & Returns
Turn Therapeutics Inc. (TTRX) has a return on equity (ROE) of -141.7%. Negative ROE indicates the company is unprofitable.
Turn Therapeutics Inc. (TTRX) had negative free cash flow of $3.9M in fiscal year 2025, likely due to heavy capital investments.